Quantbot Technologies LP purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 62,304 shares of the company’s stock, valued at approximately $3,972,000.
Several other institutional investors and hedge funds have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its position in shares of Zoetis by 13.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 13,977 shares of the company’s stock valued at $891,000 after acquiring an additional 1,692 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Zoetis by 36.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 953,167 shares of the company’s stock valued at $60,763,000 after acquiring an additional 252,553 shares during the last quarter. Stratos Wealth Partners LTD. boosted its position in shares of Zoetis by 20.0% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 33,117 shares of the company’s stock valued at $2,112,000 after acquiring an additional 5,529 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Zoetis by 3.7% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 119,905 shares of the company’s stock valued at $7,645,000 after acquiring an additional 4,326 shares during the last quarter. Finally, TCW Group Inc. boosted its position in shares of Zoetis by 28.4% during the 3rd quarter. TCW Group Inc. now owns 985,929 shares of the company’s stock valued at $62,863,000 after acquiring an additional 218,316 shares during the last quarter. Hedge funds and other institutional investors own 92.44% of the company’s stock.
Shares of Zoetis Inc. (NYSE:ZTS) traded down $0.28 during trading on Thursday, reaching $69.62. The company’s stock had a trading volume of 2,075,400 shares, compared to its average volume of 2,811,695. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The stock has a market cap of $34,061.45, a PE ratio of 32.06, a P/E/G ratio of 2.04 and a beta of 1.02. Zoetis Inc. has a 1-year low of $48.55 and a 1-year high of $70.48.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.52 EPS. sell-side analysts forecast that Zoetis Inc. will post 2.37 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.60%. Zoetis’s dividend payout ratio (DPR) is currently 22.11%.
WARNING: “Quantbot Technologies LP Invests $3.97 Million in Zoetis Inc. (ZTS)” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/16/quantbot-technologies-lp-invests-3-97-million-in-zoetis-inc-zts.html.
A number of analysts have recently issued reports on ZTS shares. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price target on shares of Zoetis in a research report on Friday, September 1st. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Thursday, October 12th. BidaskClub upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th. Finally, Deutsche Bank AG downgraded Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price target for the company. in a research report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. Zoetis presently has a consensus rating of “Buy” and a consensus price target of $67.06.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.